After Imatinib Treatment Failure in Chronic Phase CML: What Can We Do?
DOI:
https://doi.org/10.55175/cdk.v45i10.713Keywords:
CML, Imatinib, NCCNAbstract
Chronic myeloid leukemia (CML) is characterized by reciprocal translocation between chromosome 9 and 22. This translocation will activate the tyrosin kinase, leads to underlying pathogenesis of CML. Imatinib is the first line of tyrosine kinase inhibitor (TKI) to treat chronic phase of CML, but resistance has been a significant problem. NCCN has announced recommendation to treat imatinib resistance, including high-dose imatinib, the use of nilotinib or dasatinib.
Leukemia mielositik kronik(LMK) terjadi karena translokasi resiprokal antara kromosom 9 dan 22. Translokasi ini akan mengaktifkan enzim tyrosin kinase yang mencetuskan LMK. Imatinib adalah terapi lini pertama dari golongan Tyrosin Kinase Inhibitor (TKI) untuk LMK fase kronik. Namun, resistensi terhadap imatinib menjadi masalah yang cukup signifikan. NCCN telah mengeluarkan rekomendasi untuk menangani resistensi imatinib, yaitu pemberian imatinib dosis tinggi, nilotinib atau dasatinib.
Downloads
References
Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) - Pipeline Review, H2 2015. M2 Presswire 2016 Feb 01.
Stein B, Douglas Smith B. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib. ClinTher 2010 05;32(5):804-20.
Bauer S, Romvari, E. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options. Clin J Oncol Nurs 2009 10;13(5):523-34.
Jabbour E, Cortes JE, Ghanem H, O’Brien S, Kantarjian HM. Targeted therapy in chronic myeloid leukemia. Expert Rev Anticancer Ther 2008 01;8(1):99-110.
Jabbour E, Cortes JE, Kantarjian HM. Suboptimal Response to or Failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. Mayo Clin Proc 2009;84(2):161-9.
Quintás-Cardama A, Cortes J. Management of patients with resistant or refractory chronic myelogenous leukemia. Oncology 2008 Apr 15;22(4):430-7; discussion 437, 442, 446 passim.
Byrne JL, Hunter A, Lyttelton M. East Midlands Cancer Network Guidelines for the investigation and management of patients with chronic myeloid leukemia. East Midlands Cancer Network. 2015.
Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?. Mayo Clin Proc 2009;84(2):161-9.
Goulden S, Sutcliffe F, Stevens A. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib. Lancet Oncol 2012;13(2):127-8.
Hochhaus A, Müller ,M.C., Radich J, Branford S, Kantarjian HM, Hanfstein B, et al. Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value. Leukemia 2009;23(9):1628-33.
Abbott BL. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia. ClinTher 2012;34(2):272-81.
Jain P, Kantarjian H, Cortes J. Chronic myeloid leukemia: overview of new agents and comparative analysis. Curr Treatment Options in Oncol 2013;14(2):127-43.
Drugs and Therapies; Study Findings from T.P. Hughes et al. Broaden understanding of imatinib therapy (Deep molecular responses achieved in patients with CMLCP who are switched to nilotinib after long-term imatinib). Clinical Trials Week 2014 Nov 03:636.
Hughes TP, et al. Safety and efficacy of switching to nilotinib 400mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300mg twice daily. South Austral Health and Medical Res Institute. 2014.
Gugliotta G, et al. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. Am J Hematol. 2016;91
Giles FJ, et al. Nilotinib is active in chronic and accepted phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Macmillan Publ Ltd. 2010.
Giles FJ, Le Coutre PD, Pinilla-ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia 2013;27(1):107-12.
Breccia M, Binotto G. Bosutinib for chronic myeloid leukemia. Rare Cancers Therapy 08;3(1-2):35-46
Hill BG, Kota VK, Khoury HJ. Bosutinib: a third generation tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther 2014 07;14(7):765-70.
Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004 08;18(8):1321-31.
Bixby D, Talpaz M. Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia. Leukemia 2011 01;25(1):7-22.
NCCN. Chronic myelogenous leukemia. 2016.
Brien SO, et al. NCCN Task force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. 2011.
Baccarani M, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012.
Alberta Health Service. Management of chronic myeloid leukemia. Clinical Practice Guideline LYHE. 2015
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2018 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
